AI-Driven Digital Organisms Could Change Drug Discovery
AI-driven digital organisms could transform drug discovery by simulating biology across scales. Explore GenBio AI's AIDO vision and the virtual cell.
Articles, expert interviews, and insights from life sciences leaders
How Should Pharma Companies Audit AI Vendors?
“This is one of the riskiest industries there is because you're dealing with human lives, you're dealing with experimental protocols, and you're dealing with regulatory bodies where you might not get another shot at that clinical trial."
Read interview: How AI Is Opening New Opportunities in Fertility Care for Pharma
Read interview: How Should Pharma Companies Audit AI Vendors?
Read interview: Could Biological Ageing Be the Next Big Shift in Drug Discovery?
Read interview: Is AI Quietly Creating a GDPR Crisis in Clinical Research?
Read interview: How AI Is Reshaping Data Integrity in Pharma Manufacturing
Read interview: AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech
Read interview: AI in Pharma: Hype vs. What Actually Works
Read interview: How Pharmacy Innovation Is Changing Healthcare Delivery
Exclusive Pharmatica Content
Explore expert-led podcasts, pharmaceutical intelligence, life sciences insights and research-driven analysis from leading industry voices. Pharmatica delivers trusted biotech news, drug development trends and commercial intelligence for professionals across the pharmaceutical sector.
Ketryx and Accenture Build Regulated AI MedTech at Scale
Ketryx and Accenture are combining AI-native compliance infrastructure and transformation expertise to help MedTech scale regulated AI without slowing development.
Why Formulation Development Now Starts With Manufacturing
Formulation development is moving beyond drug delivery to shape manufacturing, quality, scale-up, and supply resilience across modern pharmaceutical operations.
How AI Is Opening New Opportunities in Fertility Care for Pharma
"If I had to get great minds in a room, I'd be looking at it from a tech perspective. How can we take all this knowledge, apply it to policies that can be easily distributed?” Clara Toombs, Fertilia AI.
MHRA Clarifies Licensing for Microbiome-Based Medicines
The MHRA has set out its position on microbiome-based medicinal products, confirming that a clear UK licensing route already exists for these therapies.
Enriched Clinical Trial Design: Who Gets Left Behind?
Enriched clinical trial design can improve trial efficiency, but may exclude patients from the evidence base. Explore the implications for clinical development.
Better Predictive Modelling for Better Drug Development
Discover how predictive modelling, QSP, AI, and systems biology creates better drug development by connecting biological evidence with better predictions.
BMS and NVIDIA Build Pharma’s AI Supercomputer
BMS and NVIDIA are building a powerful pharma AI factory using advanced supercomputing, AI models, and scientific data to accelerate drug discovery.
Robotics and GMP: Building the Factory of Tomorrow
Robotics in pharmaceutical manufacturing is strengthening GMP through automation, contamination control, traceability, and more consistent production processes.
FDA Oncology Trial Guidance Targets Eligibility Barriers
FDA oncology clinical trial guidance targets restrictive eligibility criteria, covering performance status, washout periods, medications, and laboratory values.
EHR Patient Recruitment Gets A Reality Check
EHR patient recruitment could improve clinical trial matching, but workflow integration, data quality, interoperability, and AI validation remain key challenges.
Could q-CAR Redefine Drug Discovery?
Find out how q-CAR drug discovery moves beyond static protein structures by linking protein dynamics, ligand activity, and AI to precision drug design.
